33 min listen
A maladaptive pathway to drug approval
FromThe BMJ Podcast
ratings:
Length:
17 minutes
Released:
Aug 19, 2016
Format:
Podcast episode
Description
The European Medicines Agency (EMA) has embraced a new model of drug testing and marketing called “adaptive pathways”, allowing new drugs for “unmet medical needs” to be launched on the market faster, on the basis of fewer data.
While industry claims this is necessary, an analysis on thebmj.com looks at the assumptions underlying the new pathway, and raises concerns about the negative impact on patient safety and the cost of healthcare.
To discuss, we're joined by Courtney Davis, senior lecturer at King’s College London, Peter Gøtzsche, director of the Nordic Cochrane Centre and Joel Lexchin, a professor at York University in Toronto.
Read the full analysis:
http://www.bmj.com/content/354/bmj.i4437
While industry claims this is necessary, an analysis on thebmj.com looks at the assumptions underlying the new pathway, and raises concerns about the negative impact on patient safety and the cost of healthcare.
To discuss, we're joined by Courtney Davis, senior lecturer at King’s College London, Peter Gøtzsche, director of the Nordic Cochrane Centre and Joel Lexchin, a professor at York University in Toronto.
Read the full analysis:
http://www.bmj.com/content/354/bmj.i4437
Released:
Aug 19, 2016
Format:
Podcast episode
Titles in the series (100)
Surgical outcome data: Last week saw the start of a campaign to publish patient death rates for individual surgeons. Bruce Keogh, medical director of the NHS in England, talks to BMJ editor in chief Fiona Godlee about the initiative and the background to it.Also, the WHO h... by The BMJ Podcast